Encapsulated Cell Technology Delivering Ciliary Neurotrophic Factor for Dry Age-Related Macular Degeneration: Neurotech


Description: Neurotech completed an 18-month Phase II clinical trial of its Encapsulated Cell Technology (ECT) — a tiny capsule implanted into the eye — for the treatment of dry age-related macular degeneration (AMD). The ECT contains retinal pigment epithelial cells which provide sustained delivery of ciliary neurotrophic factor (CNTF), a vision-preserving protein, to the retina. Two different doses of the treatment were evaluated in the study. The Foundation funded preclinical research which made this clinical study possible. Neurotech reported that 96.3 percent of participants receiving the high dose of the treatment had stable vision over a 12-month period. People with better visual acuity at the start of the treatment — 20/63 or better — appeared to benefit most. Approximately 50 people participated in the multicenter study.

Trial Status: Phase II completed; awaiting report from Neurotech on next steps.

Emerging Treatment Stabilizes Vision in People with Dry AMD

Additional information:
Neurotech dry AMD trial listing on ClinicalTrials.gov